Rhes suppression enhances disease phenotypes in Huntington's disease mice.

In Huntington's disease (HD) mutant HTT is ubiquitously expressed yet the striatum undergoes profound early degeneration. Cell culture studies suggest that a striatal-enriched protein, Rhes, may account for this vulnerability. We investigated the therapeutic potential of silencing Rhes in vivo using inhibitory RNAs (miRhes). While Rhes suppression was tolerated in wildtype mice, it failed to improve rotarod function in two distinct HD mouse models. Additionally, miRhes treated HD mice had increased anxiety-like behaviors and enhanced striatal atrophy as measured by longitudinal MRI when compared to control treated mice. These findings raise caution regarding the long-term implementation of inhibiting Rhes as a therapy for HD.

[1]  S. Snyder,et al.  Rhes, a Striatal-selective Protein Implicated in Huntington Disease, Binds Beclin-1 and Activates Autophagy* , 2013, The Journal of Biological Chemistry.

[2]  J. Cheah,et al.  PKA modulates iron trafficking in the striatum via small GTPase, Rhes , 2013, Neuroscience.

[3]  B. Lu,et al.  A novel human embryonic stem cell‐derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT‐dependent neurodegeneration , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S. Snyder,et al.  Rhes Deletion Is Neuroprotective in the 3-Nitropropionic Acid Model of Huntington's Disease , 2013, The Journal of Neuroscience.

[5]  G. Lahoste,et al.  Attenuation of Rhes Activity Significantly Delays the Appearance of Behavioral Symptoms in a Mouse Model of Huntington's Disease , 2013, PloS one.

[6]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[7]  Ryan M Spengler,et al.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. , 2011, Molecular Therapy.

[8]  S. Snyder,et al.  Rhes, a striatal–enriched small G–protein, mediates mTOR signaling and L–DOPA–induced dyskinesia , 2011, Nature Neuroscience.

[9]  O. Gokce,et al.  Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation , 2011, PloS one.

[10]  Yong Cheng,et al.  Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model , 2011, NeuroImage.

[11]  J. Steffan.  Does Huntingtin play a role in selective macroautophagy? , 2010, Cell cycle.

[12]  R. Heumann,et al.  Ras Homolog Enriched in Brain (Rheb) Enhances Apoptotic Signaling , 2010, The Journal of Biological Chemistry.

[13]  S. Snyder,et al.  Rhes, a Physiologic Regulator of Sumoylation, Enhances Cross-sumoylation between the Basic Sumoylation Enzymes E1 and Ubc9* , 2010, The Journal of Biological Chemistry.

[14]  M. MacDonald,et al.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models , 2009, Neurobiology of Disease.

[15]  S. Snyder,et al.  Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin Cytotoxicity , 2009, Science.

[16]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  G. Lahoste,et al.  The Ras homolog Rhes affects dopamine D1 and D2 receptor-mediated behavior in mice , 2008, NeuroReport.

[18]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[19]  Brian L. Gilmore,et al.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.

[20]  P. Brundin,et al.  Mutant huntingtin can paradoxically protect neurons from death , 2008, Cell Death and Differentiation.

[21]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[22]  J. Rothman,et al.  Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway , 2006, The Journal of cell biology.

[23]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Mithbaokar,et al.  Rhes Is Involved in Striatal Function , 2004, Molecular and Cellular Biology.

[25]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[26]  P. Vargiu,et al.  Thyroid hormone regulation of rhes, a novel Ras homolog gene expressed in the striatum. , 2001, Brain research. Molecular brain research.

[27]  D. Borchelt,et al.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.

[28]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.